Welcome to our dedicated page for Sonnet Biotherapeutc Hldng news (Ticker: SONN), a resource for investors and traders seeking the latest updates and insights on Sonnet Biotherapeutc Hldng stock.
Sonnet BioTherapeutics Holdings Inc. develops immunotherapeutic biologic drugs for oncology using its FHAB Fully Human Albumin-Binding platform. The platform uses a fully human single-chain antibody fragment designed to bind human serum albumin and transport large-molecule therapies toward tumor and lymphatic tissue, supporting constructs that include cytokines, peptides, antibodies and vaccines.
Company news centers on clinical and regulatory updates for targeted oncology programs, including SON-1010 or IL-12-FHAB in solid tumors and platinum-resistant ovarian cancer, as well as scientific conference presentations, shareholder voting matters, financing activity, capital-structure disclosures and governance developments.
Sonnet BioTherapeutics (NASDAQ: SONN) has secured European Patent No. EP3583125 B1 for its Fully Human Albumin Binding (FHAB®) technology, effective until February 20, 2038. The patent covers therapeutic fusion proteins utilizing FHAB for tumor targeting and extended pharmacokinetics.
The company's FHAB platform consists of a single, fully human construct with high affinity to bind to human albumin, providing an off-the-shelf solution for rapid therapeutic biologics development. This EU patent adds to Sonnet's existing global IP protection in China, Japan, Russia, and New Zealand.
Preclinical studies have demonstrated that FHAB-derived drug candidates show extended pharmacokinetics, enhanced tumor payload delivery, and improved efficacy compared to wild type cytokines. The platform enables both mono- and bi-functional mechanisms of action, potentially allowing for biological synergy between cytokines.
Sonnet BioTherapeutics (NASDAQ: SONN), a clinical-stage company focused on developing targeted immunotherapeutic drugs, has announced its participation in an upcoming healthcare investment webinar. Dr. Pankaj Mohan, the company's CEO, will present at the LIVE! with Webull Corporate Connect: Healthcare Investment Webinar on Wednesday, January 29th, 2025 at 2:40 PM ET.
The virtual biotech investment event provides an opportunity for investors to learn more about Sonnet's developments in the immunotherapeutics space. Interested participants can access the presentation through the provided registration link.
Sonnet BioTherapeutics (NASDAQ:SONN) announced the expansion of its Phase 1 SB101 clinical study of SON-1010 to evaluate its combination with trabectedin in soft-tissue sarcoma patients. The expansion follows successful monotherapy dose escalation and will explore SON-1010's immune-oncology impact at the maximum tolerated dose of 1200 ng/kg.
The study will enroll up to 18 patients with unresectable, metastatic liposarcoma or leiomyosarcoma. Enrollment is expected to complete in H1 2025, with topline safety data anticipated in H2 2025. The trial's primary outcomes include safety, tolerability, pharmacokinetics, and pharmacodynamics of SON-1010.
SON-1010, Sonnet's proprietary version of IL-12, is configured using the FHAB platform to extend half-life and bioactivity. The company believes combining SON-1010 with trabectedin could enhance local immune response in the tumor microenvironment and potentially improve treatment outcomes for soft-tissue sarcoma patients.
Sonnet BioTherapeutics (NASDAQ: SONN) has released its latest CEO Corner segment featuring CEO Pankaj Mohan, Ph.D. The segment, published on the company's website, reviews key accomplishments for 2024 and outlines targeted value-driving milestones for 2025. The content will remain accessible on www.sonnetbio.com for 90 days.
Sonnet BioTherapeutics (NASDAQ: SONN) reported fiscal year 2024 results with significant operational improvements. The company achieved a 37% reduction in total operating expenses compared to fiscal year 2023, with 43% of expenses covered by non-dilutive funding. Key developments include progress in clinical trials for SON-1010 in solid tumors and Platinum-Resistant Ovarian Cancer, and a licensing agreement for SON-080 in Diabetic Peripheral Neuropathy.
Financial results show R&D expenses decreased to $5.7M from $11.8M, and G&A expenses reduced to $6.1M from $7.1M year-over-year. The company had $0.1M cash on hand as of September 30, 2024, but secured additional funding through stock sales and tax incentives, projecting operations funded through July 2025.
Sonnet BioTherapeutics (NASDAQ:SONN) has announced a $3.9 million financing through a combination of registered direct offering and concurrent private placement. The company is selling 1,085,325 shares in the registered direct offering and 673,000 shares in the private placement, both priced at $2.23 per share. Each share comes with one warrant exercisable at $2.10 per share with a five-year term.
The transaction, expected to close around December 10, 2024, is being facilitated by Chardan as the exclusive placement agent. The proceeds will support research and development, clinical trials, and working capital needs. The offering is conducted under an effective S-3 registration statement, with the private placement shares being offered under Section 4(a)(2) of the Securities Act.
Sonnet BioTherapeutics (NASDAQ:SONN) has announced successful topline safety data from its Phase 1 SB101 trial of SON-1010 in advanced solid tumor patients. The maximum tolerated dose was established at 1200 ng/kg, with no dose-limiting toxicity or cytokine release syndrome observed.
Key findings include stable disease in 48% (10 of 21) of evaluable monotherapy patients at four months post-treatment initiation, including one patient at the maximum dose achieving a partial response with a 45% tumor reduction. Of 24 total patients, 17 (71%) showed stable disease at first follow-up. The safety profile has been favorable, with mostly mild adverse events reported.
The company is currently seeking partnership opportunities for later-stage development while continuing patient monitoring for long-term safety and tumor responses.
Sonnet BioTherapeutics (NASDAQ: SONN) announced the publication of discovery and development data for SON-1010, their lead drug candidate, in Frontiers in Immunology. The research details their albumin-binding (FHAB®) technology combined with IL-12 for improved cancer treatment delivery.
The publication highlights the identification of molecules that bind to serum albumin across multiple species and pH ranges, leading to extended half-life and improved tumor targeting. Patents for FHAB and SON-1010 have been issued in major markets including the US, China, and Japan, expiring between 2038-2039.
The company is currently conducting a Phase 1 clinical trial of SON-1010 for advanced solid tumors, with safety data expected in Q4 2024. Additionally, SON-1010 is being evaluated in a Phase 1/2a study in combination with Roche's atezolizumab for Platinum-Resistant Ovarian Cancer.
Sonnet BioTherapeutics (NASDAQ: SONN) has released a Virtual Investor segment featuring CEO Dr. Pankaj Mohan and CSO Dr. John Cini discussing their recent U.S. patent issuance. The patent covers a variant of IL-18 incorporated into two novel immunotherapeutic drug candidates: SON-1400 (IL-18BPR-FHAB) and SON-1411 (IL-18BPR-FHAB-IL12). Both candidates contain a modified version of recombinant human interleukin-18 (IL-18BPR = Binding Protein Resistant).
Sonnet BioTherapeutics (NASDAQ: SONN) has announced the pricing of an underwritten public offering of 1,111,111 shares of common stock and common warrants. The offering includes common warrants to purchase up to 2,222,222 additional shares. Each share is being sold with one common warrant at a combined price of $4.50, for total gross proceeds of approximately $5.0 million. The common warrants are exercisable for five years at $4.50 per share. The offering is expected to close around November 7, 2024. The proceeds will be used for research and development, clinical trials, working capital, liability repayment, and general corporate purposes.